Industry Alliance Office of Amsterdam Neuroscience triggers Boston-based biotech Rodin Therapeutics to launch Clinical Trial in the Netherlands

Rodin Therapeutics recently announced the launch of a clinical trial (see here); this in followup of an imaging pilot study started last year which will assess the performance of a new PET ligand that can measure synaptic density in the living brain; the outcome of the PET study should guide the Rodin’s upcoming Phase 1b trial which will be executed in the Netherlands and which is aimed to test a novel therapeutic compound, RDN-929, a potent and selective HDAC-CoREST inhibitor designed to strengthen and increase the number of synapses in patients with neurologic diseases. Prof. Arjen Brussaard, scientific director of Amsterdam Neuroscience, in collaboration with Dr. Pieter van Bokhoven, senior BD manager of the Industry Alliance Office (IAO), over the last six months pioneered this collaboration in communication with several stakeholders in and outside the Amsterdam UMC.

The Industry Alliance Office (IAO) - acting on behalf of Amsterdam Neuroscience of Amsterdam - is an embedded IXA business development office, aimed at working with pharma- and biotech-industry to negotiate research collaborations. Originally, Arjen Brussaard, scientific director of Amsterdam Neuroscience launched the IAO as an independent VUmc based office in 2013; later-on it became professionalized and integrated with IXA Amsterdam, and combines a VU/VUmc and AMC based Business Development team of five business developers and 4 staff member focussed on planning, legal and financial accounting. Since its launch, the IAO has commercialized the scientific excellence, research assets, access to patient cohorts and material, and infrastructure based on a disease-orientated approach and filled the Amsterdam Neuroscience pipeline, in assisting in the clinical validation of drug concepts and clinical compounds during both early preclinical as well as in advanced clinical stages of development. Both major pharma and midsize biotech companies have commissioned integrated projects via the IAO and in doing so, over €25 million in contracts was generated over the last 5 years.

The studies are being conducted in the Netherlands at Vrije Universiteit Medical Center in Amsterdam and University Medical Center Groningen. Prof. Philip Scheltens, director of the Alzheimer Center Amsterdam, is the leading neurologist in the clinical trial and said: “The SV2A-PET imaging tool has the potential to shape future clinical trials by offering an early signal about whether an investigational drug is driving molecular and structural changes in the brain”. Arjen Brussaard adds: “In followup of the imaging PET study, Amsterdam UMC, contracted by Rodin Therapeutics, can now take the next step and assess whether RDN-929 can arrest functional and cognitive impairment in AD patients.”

About Rodin Therapeutics
Rodin Therapeutics is discovering and developing first-in-class therapeutics for synaptopathies by applying novel chemical strategies to target specific HDAC complexes and upregulate genes critical to learning and memory. Rodin’s targeted approach to strengthening synaptic integrity, backed by a robust translational strategy, has potential across multiple neurological diseases, such as Parkinson’s, Alzheimer’s, frontotemporal dementia and schizophrenia, all of which are characterized by impaired neuronal and synaptic function. For more information, visit https://rodintherapeutics.com/.

About the IAO of Amsterdam Neuroscience
The Industry Alliance Office (IAO) - acting on behalf of Amsterdam Neuroscience of Amsterdam - is an embedded IXA business development office, aimed at working with pharma- and biotech-industry to negotiate research collaborations. Originally, Arjen Brussaard, scientific director of Amsterdam Neuroscience launched the IAO as an independent VUmc based office in 2013; later-on it became professionalized and integrated with IXA Amsterdam, and combines a VU/VUmc and AMC based Business Development team of five business developers and 4 staff member focussed on planning, legal and financial accounting. Since its launch, the IAO has commercialized the scientific excellence, research assets, access to patient cohorts and material, and infrastructure based on a disease-orientated approach and filled the Amsterdam Neuroscience pipeline, in assisting in the clinical validation of drug concepts and clinical compounds during both early preclinical as well as in advanced clinical stages of development. Both major pharma and midsize biotech companies have commissioned integrated projects via the IAO and in doing so, over €25 million in contracts was generated over the last 5 years.